Promising results on this compound derived from a post-hoc analysis including five placebo-controlled phase II clinical trials demonstrated a similar efficacy to reduce CETP activity, LDL-C, and TGs and to increase HDL-C and apoA-I in patients with and without T2DM [115]. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.